No Data
No Data
Hong Kong stock market anomaly | CRO concept stocks are all rebounding, with many stocks rising by more than 10%. The National Medical Products Administration has deployed a pilot reform of segmented production of biological products.
CRO concept stocks are all rebounding, as of the time of publication, frontage (01521) rose by 14%, to 0.57 Hong Kong dollars; pharmaron (03759) rose by 12.59%, to 14.84 Hong Kong dollars; tigermed (03347) rose by 11.11%, to 38 Hong Kong dollars; wuxi bio (02269) rose by 10.54%, to 16.78 Hong Kong dollars.
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
Pharmaron (03759.HK) received a jpmorgan shareholding of 0.4189 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on October 9, 2024, pharmaron (03759.HK) received an increase in shareholding from JPMorgan Chase & Co. at an average price of HKD 16.6004 per share, acquiring 0.4189 million shares, with a total investment of approximately HKD 6.955 million. After the increase in shareholding, JPMorgan Chase & Co. now holds a total of 15,169,407 shares, increasing their shareholding percentage from 4.89% to 5.03%.
Pharmaron (300759.SZ): Shareholder Xin Longcheng intends to reduce its shareholding by no more than 0.90%.
Kanglong Huicheng (300759.SZ) announced on October 15 that shareholder Xinlongcheng plans to reduce its shareholding by no more than 16,000,074 shares (0.90% of the total share capital after deducting the repurchased shares) through centralized bidding or block trading on the Shenzhen Stock Exchange within 3 months after 15 trading days from the date of this announcement until November 6, 2024.
Pharmaron (03759.HK) plans to hold a board of directors meeting on October 29 to approve the third-quarter performance.
Kanglong Huicheng (03759.HK) announced on October 15 that the board of directors will hold a meeting on October 29, 2024 (Tuesday) to review and approve the third quarter performance of the company and its subsidiaries for the nine months ending September 30, 2024.
PHARMARON: NOTICE OF BOARD MEETING